The US biotech and biopharma sector is entering a dense period of clinical trial updates and regulatory catalysts. I'm told that several clinical-stage biotechnology companies are actively reshuffling their pipelines and accelerating fundraising efforts. With a few key players posting better-than-expected milestone data earlier in 2026, this is shaping up to be the most significant sector momentum we have seen since late last year.

Generate Biomedicines (GENB.US)

Generate Biomedicines, an AI-driven drug discovery company pioneering generative biology, is drawing significant attention. According to people familiar with the matter, the company's strategic partnerships with Amgen and Novartis are progressing well, carrying potential milestone payments of up to USD 2.9B. In Q1 2026, the company reported having over USD 500M in cash and USD 7.2M in collaboration revenue. Its lead asset, GB-0895, is advancing through Phase 3 clinical trials, targeting a potential commercial launch by 2028.

ImmunityBio (IBRX.US)

ImmunityBio is delivering strong commercial results. The company reported record net product revenue of USD 44M in Q1 2026, representing a nearly 2.7x year-over-year increase. I'm told that the FDA has accepted its supplemental Biologics License Application (sBLA) for ANKTIVA combined with BCG, setting a PDUFA target date for January 2027. Following an exclusive agreement in May 2026 to import the Tokyo strain BCG from Japan, the company is quietly preparing for a major market rollout later this year.

CorMedix (CRMD.US)

CorMedix, which focuses on preventing bloodstream infections, recently secured a crucial legal victory. In June 2026, the US Court of Appeals for the Federal Circuit upheld a favorable ruling in its patent litigation. On the financial front, its Q1 2026 revenue topped estimates, despite an EPS of USD -0.43. According to industry insiders, its flagship product DefenCath—the only FDA-approved antimicrobial catheter lock solution in the US—is seeing increased procurement interest from large healthcare networks.

Upstream Bio (UPB.US)

Upstream Bio is making steady progress with its respiratory pipeline. The company presented new analysis data from the Phase 2 VIBRANT trial of verekitug at the EAACI congress in June 2026. As of late March 2026, the firm held USD 294.6M in cash reserves. I'm told by sources close to management that this runway comfortably supports operations into 2027, ensuring the completion of their upcoming pivotal trials.

Oncolytics Biotech (ONCY.US)

It's been a mixed bag recently for Oncolytics Biotech. On the positive side, the FDA granted Fast Track designation for its lead drug pelareorep in late July 2026. However, the company also received a non-compliance notice from Nasdaq on July 24. I'm told executives are currently evaluating strategies to regain compliance with the minimum bid price requirement before the January 2027 deadline.

Also

• Biodexa Pharmaceuticals (BDRX.US): The company recently priced a USD 3.5M equity financing and received approval in June 2026 to expand its Phase 3 Serenta trial into Canada.
• Calidi Biotherapeutics (CLDI.US): The stem cell-based biotech announced a 1:16 reverse stock split set to take effect in late July 2026, following several public offerings earlier this spring.

This article does not constitute investment advice.